Therefore, inhibition of CerS6, and perhaps CerS1 and CerS5, may serve as an attractive therapeutic approach for treating insulin resistance, obesity, fatty liver, and NASH. This evidence concerns the gene CERS5 and obesity due to melanocortin 4 receptor deficiency.